Myriad Genetics Inc

Financials

Flujo de caja de las actividades operativas 18.2 M-106.3 M-110.9 M-8.7 M1.8 M 1.8 M Flujo de caja de las actividades de inversión 274.4 M-77.5 M31.9 M-11.9 M-27.4 M -27.4 M Flujo de caja de las actividades financieras -150.6 M-8 M152.9 M-7.4 M64.2 M 64.2 M Flujo de caja libre 200 K-151.6 M-121 M-19.4 M-10 M -10 M

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity.

MYGN

Financials

Myriad Genetics Inc

Noticias

Stock Picks From Seeking Alpha's March 2026 New Analysts

Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?

Myriad Genetics (MYGN): SOTP Suggesting The Company Is Undervalued (NASDAQ:MYGN)

Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue?

Myriad Genetics recibe aprobación de la FDA para prueba de cáncer de ovario

Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics

Myriad Genetics en la Conferencia Leerink: Movimientos estratégicos en oncología

Myriad Genetics en Conferencia Leerink: Movimientos en Oncología

Myriad Genetics at Leerink Conference: Strategic Moves in Cancer Care

Raha, director ejecutivo de Myriad Genetics, compra acciones por 199.000 dólares

CEO de Raha, Myriad Genetics, compra acciones por $199 mil

Raha, Myriad Genetics CEO, buys $199k in shares